Table 3.
Home mean (SE) | Discharge mean (SE) | |
---|---|---|
Non-frail, n = 98 | 7.1 (0.44) | 7.6 (0.44) |
AF | 8.4 (0.59) | 8.6 (0.59) |
Non-AF | 5.8 (0.67) | 6.7 (0.68) |
Male | 5.7 (0.55) | 7.5 (0.55)*** |
Female | 8.6 (0.72)† | 7.8 (0.73) |
Frail, n = 47 | 10.7 (0.60)** | 9.8 (0.60)* |
AF | 12.4 (0.81)* | 11.3 (0.81) |
Non-AF | 8.9 (0.88) | 8.3 (0.89) |
Male | 11.6 (0.82)** | 10.2 (0.81) |
Female | 9.7 (0.87) | 9.4 (0.89) |
A repeated analysis of variance model was utilised for comparing the difference between frailty groups
SE standard error, *p < 0.05 compared to corresponding group of non-frail patients; **p < 0.001 compared to corresponding group of non-frail patients; ***p < 0.05 compared to number of drugs used prior to warfarin initiation (home) within the subgroup; †p < 0.05 compared to number of drugs used prior to warfarin initiation (home) in non-frail male patients